PDI Expands Contract with Dendrite; Dendrite's Leading-Edge Software, Data and Marketing Services to Enhance the Capabilities of PDI's Dedicated Sales Forces

Business Wire, August 2, 2005

BEDMINSTER & SADDLE RIVER N.J. -- Dendrite International, Inc. (NASDAQ: DRTE) a leading provider of sales, marketing, clinical, and compliance solutions for the pharmaceutical and life sciences industry and PDI, Inc. (NASDAQ: PDII), a diversified sales and marketing services provider to the biopharmaceutical, medical devices and diagnostics industries, today announced that PDI has extended its previously announced product and services contract with Dendrite. The extended contract will now provide PDI's dedicated sales teams with Dendrite's leading technologies for optimizing and coordinating promotional activities.

Under the terms of the agreement, PDI will implement Dendrite's ForceMobile(TM) handheld solution providing their sales teams with instant access to sales and customer information in the field, enabling sales representatives to provide their respective management teams with real-time data to track results and make rapid course adjustments.

In addition, PDI will implement Analyzer(TM), an easy-to-use data-viewing tool, with Web and embedded versions, which transforms industry data into information. Analyzer(TM) is useful for home office analysts in benchmarking performance to objectives and for field management in coaching and feedback.

With Dendrite's First Source(TM) Sales Applications solutions, PDI's dedicated sales forces can increase productivity and efficiency. Dendrite's comprehensive and specialized industry products and services improve PDI's ability to provide real-time data on sales performance and activity, and are designed to increase client satisfaction and impact in the field.

This contract expansion is in addition to a three-year agreement PDI's Select Access unit previously signed with Dendrite for its WebForce(TM) solution, part of Dendrite's industry-leading sales effectiveness solutions suite, First Source(TM) Sales Applications.

"PDI is committed to providing world-class, outsourced sales and marketing services for the evolving pharmaceutical industry, and this strategic alliance with Dendrite will further enhance our industry leading capabilities," said Steven K. Budd, president of PDI's Global Sales and Marketing Services Group. "It was critical for PDI to partner with a proven provider of Sales Force Automation (SFA) solutions in the healthcare space. Dendrite's industry leading technology and robust set of analytical tools will enable our sales management teams to provide feedback and make critical course adjustments real-time. Our relationship with Dendrite will make our capability unmatched in this area."

"We are pleased to advance our commitment with PDI, a company with a history of developing and implementing innovative solutions to expand their leadership position in the contract sales industry," said Bob Parisi, vice president of sales at Dendrite. "We view our ongoing work with PDI as a mutually beneficial relationship and we are pleased that PDI has chosen Dendrite to bolster and enhance its world-class outsourced sales and marketing solutions."

About Dendrite

Founded in 1986, Dendrite International, Inc., (NASDAQ: DRTE) provides diversified sales, marketing, clinical and compliance solutions to the global life sciences and pharmaceutical industry. With clients in more than 50 countries, including the world's top 20 pharmaceutical companies, Dendrite strives to be the first source for expert promotional and sales effectiveness solutions. For more information, please visit www.dendrite.com.

About PDI, Inc.

PDI, Inc. (NASDAQ:PDII) is a diversified sales and marketing services provider to the biopharmaceutical and medical devices and diagnostics industries. PDI's comprehensive set of next-generation solutions is designed to increase its clients' strategic flexibility and enhance their efficiency and profitability. Headquartered in Saddle River, NJ, PDI also has offices in Pennsylvania and Illinois. For more information, visit the Company's website at www.pdi-inc.com.

Note: Dendrite is a registered trademark of Dendrite International, Inc.

This document may contain forward-looking statements that may be identified by such forward-looking terminology as "expect," "believe," "anticipate," "will," "intend," "plan," "target," "outlook," "guidance," and similar statements or variations. Such forward-looking statements are based on our current expectations, estimates, assumptions and projections and involve significant risks and uncertainties, including risks which may result from our dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy sales and implementation cycles for certain of our solutions; our fixed expenses in relation to fluctuating revenues and variations in customers' budget cycles; dependence on certain major customers; changes in demand for our products and services attributable to any weakness experienced in the economy or mergers, acquisitions and consolidations in the pharmaceutical industry; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; international operations; integrating the entities we acquire; our ability to effectively manage our growth; the protection of our proprietary technology; our ability to compete in the Internet-related products and services market; the continued demand for Internet-related products and services; the ability of our third party vendors to respond to technological change; our ability to maintain our relationships with third-party vendors; less favorable than anticipated results from strategic relationships; dependence of data solutions on strategic relationships; events which may affect the U.S. and world economies; and catastrophic events which could negatively affect our information technology infrastructure. Other important factors that should be reviewed and carefully considered are included in the company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The company assumes no obligation for updating any such forward-looking statements to reflect actual results, changes in assumptions or other changes affecting such forward-looking statements.